Telechem International will hit the market with its own whole-human-genome chip in August, taking aim at the four players already on the market. But Telechem believes it has a secret weapon that will be very attractive to potential customers: data culled from a brand new database that the firm says is the most complete of its kind.

Telechem’s human genome chip will have 25,000 distinct oligonucleotide elements on it, said spokesman Paul Haje in an interview with BioArray News. He said the new microarray is a “one-spot, one-gene design.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.